WAVE Life Sciences (WAVE Life Sciences) Cash-to-Debt : 6.24 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. WAVE Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 6.24.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, WAVE Life Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for WAVE Life Sciences's Cash-to-Debt or its related term are showing as below:

WVE' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.35 Med: 11.55 Max: No Debt
Current: 6.24

During the past 11 years, WAVE Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 2.35. And the median was 11.55.

WVE's Cash-to-Debt is ranked worse than
50.58% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs WVE: 6.24

WAVE Life Sciences Cash-to-Debt Historical Data

The historical data trend for WAVE Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

WAVE Life Sciences Cash-to-Debt Chart

WAVE Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

4.52

6.30

5.03

2.35

6.24

WAVE Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.35	5.67	4.92	4.16	6.24

Competitive Comparison of WAVE Life Sciences's Cash-to-Debt

For the Biotechnology subindustry, WAVE Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WAVE Life Sciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's Cash-to-Debt falls into.

WAVE Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

WAVE Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	200.351	/	(6.714	+	25.404)
	=	6.24

WAVE Life Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	200.351	/	(6.714	+	25.404)
	=	6.24

WAVE Life Sciences (NAS:WVE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

WAVE Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

WAVE Life Sciences (WAVE Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

1U5:Germany

Address

Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936

Website

https://www.wavelifesciences.com

WAVE Life Sciences Ltd is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.

Executives

Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kyle Moran	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chandra Vargeese	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Paul Bolno	director, officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A. Panzara	officer: Franchise Lead, Neurology	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero	officer: Interim CFO	733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Heidi L Wagner	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Amy Pott	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Mark Corrigan	director